Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 27.67% is 39% below its 5-year average of 45.70%, near the low end of its 5-year range (18.84%–141.12%).
2.86% above its 12-month average of 26.90%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
27.67%
RETURN ON EQUITY (ROE) AVG TTM
26.90%
RETURN ON EQUITY (ROE) AVG 3Y
55.97%
RETURN ON EQUITY (ROE) AVG 5Y
45.70%
RETURN ON EQUITY (ROE) AVG 10Y
-146.03%
RETURN ON EQUITY (ROE) AVG 15Y
56.11%
RETURN ON EQUITY (ROE) AVG 20Y
56.57%
CURRENT VS TTM AVG
+2.86%
CURRENT VS 3Y AVG
-50.56%
CURRENT VS 5Y AVG
-39.46%
CURRENT VS 10Y AVG
+118.95%
CURRENT VS 15Y AVG
-50.69%
CURRENT VS 20Y AVG
-51.08%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+106.80%
vs the sector median at left
GSK plc
Market Cap
$102.15B
Return on Equity (ROE)
27.67%
TTM Avg
26.90%
3Y Avg
55.97%
5Y Avg
45.70%
Market Cap
$105.24B
Return on Equity (ROE)
70.66%
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$89.19B
Return on Equity (ROE)
-112.56%
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$115.78B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$119.12B
Return on Equity (ROE)
6.16%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$84.25B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$82.38B
Return on Equity (ROE)
13.65%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$76.22B
Return on Equity (ROE)
14.71%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$129.92B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $102.15B | 27.67% | 26.90% | 55.97% | 45.70% |
| McKesson Corporation (MCK)vs › | $105.24B | 70.66% | -189.06% | -180.53% | 3473.86% |
| HCA Healthcare, Inc. (HCA)vs › | $89.19B | -112.56% | -171.53% | -210.62% | -155.29% |
| Medtronic plc (MDT)vs › | $115.78B | 9.70% | 9.71% | 8.51% | 8.44% |
| CVS Health Corp. (CVS)vs › | $119.12B | 6.16% | 4.23% | 6.35% | 7.74% |
| Elevance Health Inc. (ELV)vs › | $84.25B | 11.06% | 13.69% | 14.71% | 14.93% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $82.38B | 13.65% | 14.72% | 15.95% | 23.11% |
| Boston Scientific Corporation (BSX)vs › | $76.22B | 14.71% | 10.21% | 8.16% | 6.40% |
| Bristol-Myers Squibb Company (BMY)vs › | $129.92B | 41.59% | -8.30% | 7.76% | 4.45% |
| Cigna Corporation (CI)vs › | $72.17B | 15.05% | 11.32% | 12.19% | 12.83% |
ROE
27.7%
ROA
7.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 34.96% |
| 2024-12-31 | 18.84% |
| 2023-12-31 | 28.96% |
| 2022-12-31 | 141.12% |
| 2021-12-31 | 21.50% |
| 2020-12-31 | 28.83% |
| 2019-12-31 | 30.74% |
| 2018-12-31 | 95.82% |
| 2017-12-31 | -2252.94% |
| 2016-12-31 | 81.14% |
| 2015-12-31 | 164.69% |
| 2014-12-31 | 64.65% |
| 2013-12-31 | 77.69% |
| 2012-12-31 | 77.44% |
| 2011-12-31 | 65.50% |
| 2010-12-31 | 18.39% |
| 2009-12-31 | 55.28% |
| 2008-12-31 | 58.03% |
| 2007-12-31 | 54.35% |
| 2006-12-31 | 57.40% |
| 2005-12-31 | 64.12% |
| 2004-12-31 | 68.24% |
| 2003-12-31 | 58.08% |
| 2002-12-31 | 59.79% |
| 2001-12-31 | 41.15% |
| 2000-12-31 | 53.97% |
| 1999-12-31 | 57.64% |
| 1998-12-31 | 67.95% |
| 1997-12-31 | 100.38% |
| 1996-12-31 | 163.02% |
